These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 9664130)

  • 1. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5.
    Modjtahedi H; Affleck K; Stubberfield C; Dean C
    Int J Oncol; 1998 Aug; 13(2):335-42. PubMed ID: 9664130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.
    Rusnak DW; Lackey K; Affleck K; Wood ER; Alligood KJ; Rhodes N; Keith BR; Murray DM; Knight WB; Mullin RJ; Gilmer TM
    Mol Cancer Ther; 2001 Dec; 1(2):85-94. PubMed ID: 12467226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor.
    Modjtahedi H; Eccles S; Sandle J; Box G; Titley J; Dean C
    Cancer Res; 1994 Apr; 54(7):1695-701. PubMed ID: 8137284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction.
    Modjtahedi H; Eccles S; Box G; Styles J; Dean C
    Br J Cancer; 1993 Feb; 67(2):254-61. PubMed ID: 7679281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system.
    Sriuranpong V; Park JI; Amornphimoltham P; Patel V; Nelkin BD; Gutkind JS
    Cancer Res; 2003 Jun; 63(11):2948-56. PubMed ID: 12782602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor.
    Zhang X; Zhang H; Tighiouart M; Lee JE; Shin HJ; Khuri FR; Yang CS; Chen Z'; Shin DM
    Int J Cancer; 2008 Sep; 123(5):1005-14. PubMed ID: 18546267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa).
    Barnes CJ; Bagheri-Yarmand R; Mandal M; Yang Z; Clayman GL; Hong WK; Kumar R
    Mol Cancer Ther; 2003 Apr; 2(4):345-51. PubMed ID: 12700278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.
    Pollack VA; Savage DM; Baker DA; Tsaparikos KE; Sloan DE; Moyer JD; Barbacci EG; Pustilnik LR; Smolarek TA; Davis JA; Vaidya MP; Arnold LD; Doty JL; Iwata KK; Morin MJ
    J Pharmacol Exp Ther; 1999 Nov; 291(2):739-48. PubMed ID: 10525095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468.
    Modjtahedi H; Styles JM; Dean CJ
    Br J Cancer; 1993 Feb; 67(2):247-53. PubMed ID: 8094290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-EGFR monoclonal antibodies which act as EGF, TGF alpha, HB-EGF and BTC antagonists block the binding of epiregulin to EGFR-expressing tumours.
    Modjtahedi H; Komurasaki T; Toyoda H; Dean C
    Int J Cancer; 1998 Jan; 75(2):310-6. PubMed ID: 9462724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells.
    Thelemann A; Petti F; Griffin G; Iwata K; Hunt T; Settinari T; Fenyo D; Gibson N; Haley JD
    Mol Cell Proteomics; 2005 Apr; 4(4):356-76. PubMed ID: 15657067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma.
    Baba Y; Maeda T; Suzuki A; Takada S; Fujii M; Kato Y
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
    Benavente S; Huang S; Armstrong EA; Chi A; Hsu KT; Wheeler DL; Harari PM
    Clin Cancer Res; 2009 Mar; 15(5):1585-92. PubMed ID: 19190133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential modulation of proliferation, matrix metalloproteinase expression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands.
    O-charoenrat P; Rhys-Evans P; Court WJ; Box GM; Eccles SA
    Clin Exp Metastasis; 1999; 17(7):631-9. PubMed ID: 10845563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice.
    Kunkel MW; Hook KE; Howard CT; Przybranowski S; Roberts BJ; Elliott WL; Leopold WR
    Invest New Drugs; 1996; 13(4):295-302. PubMed ID: 8824347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
    Lu H; Li X; Lu Y; Qiu S; Fan Z
    Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The binding of HB-EGF to tumour cells is blocked by mAbs which act as EGF and TGF alpha antagonists.
    Modjtahedi H; Dean C
    Biochem Biophys Res Commun; 1995 Feb; 207(1):389-97. PubMed ID: 7857293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression.
    Anderson NG; Ahmad T; Chan K; Dobson R; Bundred NJ
    Int J Cancer; 2001 Dec; 94(6):774-82. PubMed ID: 11745477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.